Table 2 Summary of Current Clinical Trials for Bone Metastatic Cancers

Radiotherapy

Hypofractionated radiotherapy regimen

NCT02376322

SBRT vs EBRT

NCT00922974

1 vs 2 fractions of EBRT

NCT02699697

Dose regimen of radiotherapy

NCT02163226

SBRT + ADT

NCT02563691

IMRT vs EBRT

NCT02832830

EBRT +/− hyperthermia

NCT01842048

Surgery +/− postoperative radiotherapy

NCT02705183

Treatment of opiod refractory pain with pituitary radiosurgery

NCT02637479

LHRH agonist + Enzulutamide +/− SBRT

NCT02685397

ADT +/− radiotherapy

NCT02913859

SBRT + anti PD-1 antibody

NCT02303366

SBRT with sunitinib

NCT02019576

FDG-PET guided radiotherapy with conventional dose vs FDG-PET with SBRT dose escalation

NCT01429493

Conventional radiotherapy vs SBRT

NCT02364115

SBRT workflow

NCT02145286

SBRT

NCT02880319

Single fraction SSRTvs multple fraction SSRT

NCT02608866

Zoledronic acid + high dose radiotherapy or low dose radiotherapy

NCT02480634

Conventional radiotherapy vs SBRT

NCT02512965

Observation vs SBRT vs SBRT +18F–DCFPyL

NCT02680587

Small Molecule

Zoledronic acid (prevention)

NCT02622607

NCT02286830

Docetaxel + zoledronic acid +/− apatinib

NCT03127319

Dose escalation of sirolimus + cyclophosphamide, methotrexate, zolendronic acid

NCT02517918

Dosing scheducle of pamidronate or denosumab or zolendronate

NCT02721433

Zoledronic acid or densoumab +/− amorphous calcium carbonate

NCT02864784

Calcifediol + denosumab or zoledronic acid

NCT02274623

Cabozantinib

NCT01703065

Receptor tyrosine kinase inhibitor

NCT02219711

Selinexor (selective inhibitor of nuclear export)

NCT02215161

Docetaxel + clarithromycin vs cabazitaxel + clarithromycin

NCT03043989

Enzalutamide + LHRH analogue therapy vs bicalutamide + LHRH analogue therapy

NCT02058706

Copper + disulfram

NCT02963051

Palbociclib + tamoxifen

NCT02668666

Denosumab + enzalutamide +/− abiraterone and prednisone

NCT02758132

Mab

Dosing schedule of denosumab

NCT02051218

Denosumab in patients with circulating tumor cells plus bone metastasis

NCT03070002

Denosumab + hormonal therapy

NCT01952054

Pembrolizumab

NCT02787005

Radium 223 +/− pembrolizumab

NCT03093428

Radioisotopes

ADT +/− radium 223

NCT02582749

Hormonal therapy +/− radium 223

NCT02258464

EBRT +/− radium 223

NCT02484339

Radium 223

NCT03062254

NCT02390934

NCT02283749

NCT03002220

NCT02312960

Cellular therapy

Genetically modified dendritic cells + cytokine induced killer cells

NCT02688686

Sipuleucel-T +/− radiation therapy

NCT01833208

Engineered autologous T cells + cyclophosphamide

NCT01140373

Dendritic cell based cryoimmunotherapy + cyclophosphamide +/− ipilimumab

NCT02423928

Sipuleucell-T +/− radium 223

NCT02463799

HIFU

HIFU vs EBRT

NCT01091883

MRI guided HIFU

NCT03106675

NCT02718404

NCT00981578

NCT01833806

NCT02616016

Surgery

Surgery +/− radiation therapy

NCT01428895

Radical Prostatectomy + ADT

NCT02454543

Intraoperative radiotherapy with kyphoplasty

NCT02480036

Kyphoplasty vs vertebroplasty

NCT02700308

Resection of primary breast tumor in stage IV patients

NCT02125630

Other

Modified Polio virus

NCT03071328

Somatostatin

NCT02631616

Intermittant Fasting

NCT02710721

Bifunctional macromolecular poly-bisphosphonate

NCT02825628

Thermal ablation + steriotactic radiosurgery

NCT02713269

Pembrolizumab + pTVG-HP plasmid DNA vaccine

NCT02499835

Isometric resistance training

NCT02847754

Fentanyl transmucosal

NCT02426697

Fentynl intranasal

NCT03071744

Tanezumab (for pain)

NCT02609828

QOL with denosumab or bisphosphonates

NCT02839291

Cryoablation

NCT02511678